Two recent studies that involve perturbing tumour blood supply provide
new hope for anti-cancer therapies. The first uses elegant molecular
engineering to achieve tumour-specific blood clots and the second repo
rts the identification of a natural inhibitor, endostatin, which is pr
oduced from tumour extracellular matrix.